Figure 4
The representative photomicrographs of mouse tumor tissues with HE (200×).
The exponentially growing Huh7 cells (107 cells/mL) with >95% viability were subcutaneously injected into the loose skin between the shoulder blades and left front leg of the recipient mice. All of the following treatments were started when the tumors reached a volume around 500 mm. The mice were randomly divided into five groups with the use of a randomization chart (n = 8 in each group). The high-dose BZG-4000 group was orally administrated BZG-4000 at 40 mg/kg/day for 21 consecutive days. The medium-dose BZG-4000 group was orally administrated BZG-4000 at 20 mg/kg/day for 21 consecutive days. The low-dose BZG-4000 group was orally administrated BZG-4000 at 10 mg/kg/day for 21 consecutive days. The sorafenib group, positive control group, was treated with sorafenib at 20 mg/kg/day by intragastric injection for 21 consecutive days. The model group was orally administrated vehicle at 20 mg/kg/day for 21 consecutive days. The sorafenib dose was based on standard clinical doses. During the treatment period, 0, 1, 2, 2 and 3 mice, respectively to the above listed group, died. The gels have been run under the same experimental conditions. Data is shown as mean ± SD. (n = 8, 7, 6, 6, 5 respectively in each group). The significant difference was set at a* P < 0.05, compared with the model group; # P < 0.05, compared with the sorafenib group (ANOVA).
